Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells-Reference-Cited by-同舟云学术

Vaccination of a Melanoma Patient with Mature Dendritic Cells Pulsed with MAGE-3 Peptides Triggers the Activity of Nonvaccine Anti-Tumor Cells

Published:2008-02-21 Issue:5 Volume:180 Page:3585-3593
ISSN:0022-1767
Container-title:The Journal of Immunology
language:en
Short-container-title:J Immunol

Author:

Carrasco Javier,Van Pel Aline,Neyns Bart,Lethé Bernard,Brasseur Francis,Renkvist Nicolina,van der Bruggen Pierre,van Baren Nicolas,Paulus Robert,Thielemans Kris,Boon Thierry,Godelaine Danièle

Publisher

The American Association of Immunologists

Subject

Immunology,Immunology and Allergy

Reference40 articles.

1. Clinical and Immunologic Results of a Randomized Phase II Trial of Vaccination Using Four Melanoma Peptides Either Administered in Granulocyte-Macrophage Colony-Stimulating Factor in Adjuvant or Pulsed on Dendritic Cells

2. Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed Schedule

3. Active-specific immunotherapy for melanoma.

Cited by 83 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy;Biomedicine & Pharmacotherapy;2024-08

2. Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma;Heliyon;2023-03

3. Cancer-testis non-coding RNA LEF1-AS1 regulates the nuclear translocation of PDCD5 and suppresses its interaction with p53 signaling: a novel target for immunotherapy in esophageal squamous cell carcinoma;Carcinogenesis;2023-02-24

4. Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer—a retrospective cohort study;Translational Lung Cancer Research;2023-02

5. Unfavorable tumor responses to immunotherapy in the liver: Lessons learned from clinical and preclinical studies;Journal of Cancer Research and Practice;2023